Skip to main content
Equibles
PDEX logo

PDEX · Pro Dex Inc

Track PDEX — free

Use PDEX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PDEX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$62.19 -0.19 (-0.30%)
Russell 2000 member Rebalance outlook locked
Market Cap
$199.82M
Shares
3.20M
Volume · Oct 23 48.96K Avg daily vol (3M) 67.12K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$62.38 Open$60.30 Day$60.30–63.24 52W close$26.36–73.41 Avg vol 30d56K Short int199K · 6.2% float · 2.9d Short vol67% DataJan 2020–Oct 2026 Filing10-K · Sep 3

Up next

Latest filing: 10-K
filed Sep 3, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$77.55M
Trailing 12 months
Net income (TTM)
$13.66M
Trailing 12 months
Revenue growth YoY
+16.6%
Year over year
Operating margin
16.8%
Trailing 12 months
P / E (TTM)
15.1
Trailing earnings · reciprocal yield 6.6%
FCF yield
3.5%
TTM · current market cap
Return on invested capital
17.7%
Trailing 12 months
Net cash
−$8.17M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-2.0%
Year over year · fewer shares
Price change (1Y)
+136.6%
Trailing year
Short interest
6.2%
Latest settlement · 2.9 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
▲24.7% $14.89M $2.47M '25 Q1 ▲33.4% $16.79M $2.04M '25 Q2 ▲21.8% $17.41M $3.27M '25 Q3 ▲16.4% $17.49M $1.20M '25 Q4* ▲24.4% $18.53M $4.68M '26 Q1 ▲11.1% $18.66M $2.19M '26 Q2 ▲14.6% $19.95M $3.94M '26 Q3 LATEST ▲16.6% $20.41M $2.86M '26 Q4*

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19 · elevated Equity put/call 0.69
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +11%
above
Price vs 50-day avg −5%
below
RSI (14) 47
neutral
MACD trend Negative
52-week position 77%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −15%
trailing
6-month return +29%
trailing
YTD return +62%
this year
Relative strength +23%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $65 › 200d $56 — 50d above 200d
Institutional flow Accumulating
11 of 66 funds reported for Sep 30 · net +18.0K sh shares · +5 new
Insider flow Distributing
Net -$141.0K over 90 days · 100% sells
Short interest Falling
6.22% of float · ▼ -5.0% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
66 holders — near 3-yr high, broad support
Squeeze score 57
elevated · 0–100
Fundamentals
Excellent
Revenue growth +16%
Y/Y
Gross margin 31%
expanding
EPS growth +54%
Y/Y
Free cash flow $6.8M
Valuation P/E 15.1
below peers
Balance sheet $9.1M
net debt
Quant / Vol
risk profile
Very High
Volatility 58%
annualized · 1-yr
Max drawdown −21%
past year
ATR 4.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+11% Bullish
Price vs 50-day avg
−5% Neutral
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
77% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $65 › 200d $56 — 50d above 200d
Institutional flow Accumulating
11 of 66 funds reported for Sep 30 · net +18.0K sh shares · +5 new
Insider flow Distributing
Net -$141.0K over 90 days · 100% sells
Short interest Falling
6.22% of float · ▼ -5.0% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
66 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $26 Now $62 · 77% Range high $73
vs 200-day avg +11% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Employee turnover 21% fiscal 2026 filing —
Employees 206 fiscal 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PDEX
Pro Dex Inc
this stock
$199.82M +62.1% +16.5% 15.1 6.2%
ISRG
Intuitive Surgical Inc
 $153.86B -21.6% +20.5% 53.8 2.1%
BDX
Becton Dickinson & Co
 $54.31B — +8.2% — 3.6%
MDLN
Medline Inc.
 $45.86B -17.0% +11.5% — 4.0%
RMD
Resmed Inc
 $36.50B +5.1% +13.4% 24.3 8.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
70
% held
23.5%
Reported
11 of 66
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
93
View
Short & Settlement
Short Interest Falling
Shares short
199.4K
Days to cover
2.9d
Change
-10.5K sh
View
Short Volume
Short vol %
67%
As of
Oct 22, 2026
Short Total
View
Fails to Deliver
FTD shares
335
Value
$24.1K
As of
Sep 17, 2026
View
Off-Exchange
Off-exchange %
31.9%
Week of
Sep 14, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$141.0K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$77.5M
Net income (FY)
$13.7M
EPS diluted
$4.12
View
Buybacks
Authorized
shares 1.0M
View
Filings
SEC Filings
Latest
DEF 14A
Filed
Oct 6, 2026
This year
14
View
Proposed Sales
Value
$1.3M
Shares
20.0K
Filed
Sep 9, 2026
View

Performance

5D 20D 120D MTD YTD
PDEX +3.9% -14.6% +29.0% -9.6% +62.1%
SPY -1.0% -0.4% +6.0% +0.2% +12.0%
vs SPY +4.9% -14.2% +23.0% -9.8% +50.1%

Capital returns

Buyback program · as of Sep 30, 2022
Authorized
shares 1.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 788920 CUSIP 74265M205 13F (30d) 10 filings 10 filers Visit website Investor relations